KR920011516A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR920011516A
KR920011516A KR1019910022557A KR910022557A KR920011516A KR 920011516 A KR920011516 A KR 920011516A KR 1019910022557 A KR1019910022557 A KR 1019910022557A KR 910022557 A KR910022557 A KR 910022557A KR 920011516 A KR920011516 A KR 920011516A
Authority
KR
South Korea
Prior art keywords
acid
aqueous solution
hct
cellulose derivative
concentration
Prior art date
Application number
KR1019910022557A
Other languages
English (en)
Other versions
KR100253862B1 (ko
Inventor
아빈트 투더
다이아나 라이맨 캐더린
Original Assignee
베르너 발데그
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909026882A external-priority patent/GB9026882D0/en
Priority claimed from GB919119048A external-priority patent/GB9119048D0/en
Application filed by 베르너 발데그, 시바-가이기 에이지 filed Critical 베르너 발데그
Publication of KR920011516A publication Critical patent/KR920011516A/ko
Application granted granted Critical
Publication of KR100253862B1 publication Critical patent/KR100253862B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

내용 없음

Description

약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 물, 사람 칼시토닌(hCT) 및 셀룰로오즈 유도체 및 /또는 산 (이때, 산의 형태 및 양은 염 또는 완충액의 부재하에서 수용액의 안정성이 성취되도록 선택된다)을 포함하고, 25℃에서 24시간 이상 동안 hCT원섬유가 발생하지 않는 hCT의 안정한 수용액.
  2. 제1항에 있어서, hCT를 0.5내지 10㎎/㎖로 함유하는 수용액.
  3. 제1항 또는 제2항에 있어서, 셀룰로오즈 유도체가 메틸 셀룰로오즈, 하이드록시프로필 메틸 셀룰로오즈 또는 덱스트란인 수용액.
  4. 제3항에 있어서, 셀룰로오즈 유도체의 농도가 0.1 내지 2중량 %인 수용액.
  5. 제1항 또는 제2항에 있어서, 산이 포름산, 아세트산, 아스코르브산, 염산, 석신산, L-글루팀산, 말론산, 글루타르산, 아디프산, 시트르산, L-α-타르타르산, DL-타르타르산, 에틸렌 디아민 테트라아세트산 및 페놀중에서 선택된 수용액.
  6. 제5항에 있어서, 산의 농도가 1중량 %이하인 수용액.
  7. 제6항에 있어서, 산의 농도가 0.0001중량 %내지 0.1 중량 %인 수용액.
  8. 제1항 내지 제7항중 어느 한 항에 있어서, 점도 증진 팽윤제, 당 및 / 또는 기타 첨가제도 함유하는 수용액.
  9. 제8항에 있어서, 슈크로오즈, 프럭토오즈, 글루코오즈, 락토오즈, 만니톨, 트레할로오즈, 에탄올, 소 혈청 알부민, 라이소자임, 벤즈알코늄 클로라이드, 벤조에토늄 클로라이드, 3급 암모늄 염 및 /또는 클로르헥시딘 디아세테이트를 함유하는 수용액.
  10. 셀룰로오즈 유도체 및 / 또는 산의 수용액을 hCT분말에 가한후 교반하여 분말을 용해시킨 다음 경우에 따라 기타의 성분을 가하여 제1항 내지 제9항중 어느 한 항에 따른 안정한 hCT 수용액을 제조하는 방법.
  11. 제10항에 있어서, 교반을 불활성 가스 대기하에서 수행하는 방법.
  12. 제10항 또는 제11항에 있어서, 생성된 용액을 진공하에서 탈기시키는 방법.
  13. 제10항 내지 제12항중 어느 한 항에 있어서, hCT분말을 먼저 수성산에 용해시킨후 셀루로오즈 유도체의 수용액을 가하는 방법.
  14. ※ 참고사항：최초출원 내용에 의하여 공개하는 것임.
KR1019910022557A 1990-12-11 1991-12-10 사람 칼시토닌의 안정한 수용액 및 이의 제조방법 KR100253862B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9026882.2 1990-12-11
GB909026882A GB9026882D0 (en) 1990-12-11 1990-12-11 Pharmaceutical compositions
GB9119048.8 1991-09-06
GB91190488 1991-09-06
GB919119048A GB9119048D0 (en) 1991-09-06 1991-09-06 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR920011516A true KR920011516A (ko) 1992-07-24
KR100253862B1 KR100253862B1 (ko) 2000-09-01

Family

ID=26298092

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910022557A KR100253862B1 (ko) 1990-12-11 1991-12-10 사람 칼시토닌의 안정한 수용액 및 이의 제조방법

Country Status (16)

Country Link
EP (1) EP0490549B1 (ko)
JP (1) JP3179538B2 (ko)
KR (1) KR100253862B1 (ko)
AT (1) ATE124869T1 (ko)
AU (1) AU653371B2 (ko)
CA (1) CA2057291C (ko)
DE (1) DE69111205T2 (ko)
DK (1) DK0490549T3 (ko)
ES (1) ES2074236T3 (ko)
HU (1) HU213204B (ko)
IE (1) IE66398B1 (ko)
IL (1) IL100239A (ko)
MX (1) MX9102446A (ko)
NZ (1) NZ240901A (ko)
PH (1) PH30776A (ko)
PT (1) PT99727B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5397479A (en) * 1993-04-26 1995-03-14 International Remote Imaging Systems, Inc. Composition and method for enrichment of white blood cells from whole human blood
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
JP2000512671A (ja) 1996-06-14 2000-09-26 エミスフェアー テクノロジーズ インク マイクロカプセル化香料及び調製方法
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
KR100611559B1 (ko) * 1998-05-08 2007-04-25 동아제약주식회사 칼시토닌을 함유한 비강투여용 약제학적 조성물
DE60038386T2 (de) * 1999-09-08 2009-04-23 Chugai Seiyaku K.K. Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
JP3498041B2 (ja) 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657858A5 (de) * 1983-06-27 1986-09-30 Ciba Geigy Ag Substanz aus der gruppe der calcitonine.
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE68907066T2 (de) * 1988-01-29 1993-12-16 Sumitomo Pharma Verbesserte Formulierungen mit kontrollierter Abgabe.
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
JPH02174726A (ja) * 1988-12-23 1990-07-06 Toyo Jozo Co Ltd エルカトニン水溶液組成物の安定化法
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物

Also Published As

Publication number Publication date
IE914294A1 (en) 1992-06-17
PT99727A (pt) 1992-10-30
DE69111205D1 (de) 1995-08-17
DE69111205T2 (de) 1996-01-04
EP0490549B1 (en) 1995-07-12
HUT59832A (en) 1992-07-28
HU913887D0 (en) 1992-02-28
NZ240901A (en) 1993-03-26
AU8889891A (en) 1992-06-18
PT99727B (pt) 1999-05-31
MX9102446A (es) 1992-07-01
AU653371B2 (en) 1994-09-29
EP0490549A1 (en) 1992-06-17
DK0490549T3 (da) 1995-08-21
KR100253862B1 (ko) 2000-09-01
CA2057291C (en) 2003-09-09
IL100239A (en) 1996-06-18
JP3179538B2 (ja) 2001-06-25
HU213204B (en) 1997-03-28
CA2057291A1 (en) 1992-06-12
ATE124869T1 (de) 1995-07-15
IL100239A0 (en) 1992-09-06
ES2074236T3 (es) 1995-09-01
IE66398B1 (en) 1995-12-27
JPH06340547A (ja) 1994-12-13
PH30776A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
KR920011516A (ko) 약제학적 조성물
RU2098130C1 (ru) Фармацевтический препарат гормона роста и его стабилизатор
KR850007378A (ko) 인터로이킨-2의 안정화 조성물의 제조방법
RU2001108569A (ru) Стабилизированная фармацевтическая композиция в лиофилизированной форме
CA2341568A1 (en) Stabilized pharmaceutical composition in lyophilized form
US4409233A (en) Highly concentrated preparations of dopa compounds
KR970061270A (ko) 히토성장호르몬을 함유하는 의약제제
JP3748970B2 (ja) ヒアルロン酸ナトリウム含有水溶液
JP3140409B2 (ja) 安定なプロスタグランジンｅ１−含有注射剤組成物
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
JPS6393712A (ja) 有機酸を有効成分とする水性液剤の製造法
US4128632A (en) Solubilization of Rafoxanide
US4326033A (en) Modified urokinase having extended activity and method of making
SE460638B (sv) Suppositoriepreparat med foerbaettrad absorptionsegenskap
KR910009253A (ko) 경구용 액제
JPS5914447B2 (ja) ｐＨおよび色安定化非経口投与用水性抗性物質組成物
JPH05306235A (ja) パラサイロイドホルモン類の安定化組成物
KR910005886A (ko) 안정화 백혈구 인터페론
WO2007022105A2 (en) Stable pharmaceutical compositions, processes for making the same, and methods of their use
JPH07157431A (ja) 安定なプロスタグランジンｅ製剤
EP0508435B1 (en) Pharmaceutical composition of stabilized [Leu 13]-motilin-Hse
US4954522A (en) Lyophilized preparation of platinum compound
EP0743854B1 (en) Anti-tumour medical preparation on the basis of carboplatin and the method of its production
US2944940A (en) Adrenocorticotrophin and zinc composition
KR860000073A (ko) 기계적 응력에 대해 안정화된 수성인슐린 제제의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
N231 Notification of change of applicant
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090123

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee